Trace metals and degenerative diseases of the skeleton.

Aluminum related osteodystrophy is the most important manifestation of trace metal toxicity related to degenerative diseases of the skeleton. Aluminum overload occurs in chronic renal failure patients on hemodialysis treatment and results from transfer from dialysis solutions and from oral intake of aluminum containing phosphate binding gels. Laboratory diagnosis involves serum and bone analysis and bone staining for aluminum. A challenge test with desferrioxamine also aids in the diagnosis. Electrothermal atomic absorption spectrometry is widely used for aluminum detection. Guidelines for toxic concentrations of aluminum have been established.

[1]  S. Ott,et al.  Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. , 1984, Annals of internal medicine.

[2]  H. Malluche,et al.  The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. , 1984, The New England journal of medicine.

[3]  R. Bertholf,et al.  Electrothermal atomic absorption spectrometric determination of aluminum in serum with a new technique for protein precipitation. , 1984, Clinical chemistry.

[4]  S. Hopfer,et al.  Rapid analysis of nickel in serum and whole blood by electrothermal atomic absorption spectrophotometry. , 1984, Annals of clinical and laboratory science.

[5]  R. Bertholf,et al.  Aluminum Hyoroxioe-Inouceo Osteomalacia, Encephalopathy ANO Hyperaluminemia in CAPO. Treatment with Oesferrioxamine , 1984 .

[6]  P. R. Wilson,et al.  Animal model of aluminum-induced osteomalacia: role of chronic renal failure. , 1983, Kidney international.

[7]  C. Kingswood,et al.  FRACTURE OSTEOMALACIA, CAPD, AND ALUMINIUM , 1983, The Lancet.

[8]  D. Trauner,et al.  Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide. , 1983, Pediatrics.

[9]  J. Denton,et al.  Treatment of fracturing renal osteodystrophy by desferrioxamine. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[10]  H. Y. Elder,et al.  HYPERCALCAEMIC OSTEOMALACIA DUE TO ALUMINIUM TOXICITY , 1982, The Lancet.

[11]  S. Ott,et al.  The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. , 1982, The New England journal of medicine.

[12]  D. Kerr,et al.  Dialysis encephalopathy, bone disease and anaemia: the aluminum intoxication syndrome during regular haemodialysis. , 1981, Journal of clinical pathology.

[13]  J. Zingraff,et al.  Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization. , 1981, Kidney international.

[14]  J. Day,et al.  SUCCESSFUL REMOVAL OF ALUMINIUM FROM PATIENT WITH DIALYSIS ENCEPHALOPATHY , 1980, The Lancet.

[15]  J. Versieck,et al.  Normal levels of trace elements in human blood plasma or serum , 1980 .

[16]  T. Drüeke.  Dialysis osteomalacia and aluminum intoxication. , 1980, Nephron.

[17]  H. A. Ellis,et al.  Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation. , 1979, Journal of clinical pathology.

[18]  T. Feest,et al.  FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY An Epidemiological Survey , 1979, The Lancet.

[19]  T. Feest,et al.  OSTEOMALACIC DIALYSIS OSTEODYSTROPHY: EVIDENCE FOR A WATER-BORNE ÆTIOLOGICAL AGENT, PROBABLY ALUMINIUM , 1978, The Lancet.

[20]  J. S. Hislop,et al.  Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. , 1977, British medical journal.

[21]  C. Ogg,et al.  Aluminium in Bone from Patients with Renal Failure , 1971, British medical journal.

[22]  C. R. George,et al.  Active Uptake of Copper and Zinc during Haemodialysis , 1969, British medical journal.